NEW YORK (GenomeWeb News) — Ipsogen today said it has co-exclusively licensed a biomarker from Xenomics linked to acute myeloid leukemia in order to develop and sell tests for the disease.  
  
Ipsogen’s diagnostics, which will be designed to stratify and monitor AML patients, will be based on NPM1 mutations that will integrate Ipsogen’s quantitative and standardized technology, including its FusionQuant and ProfileQuant tools, according to a statement.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.

Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.

In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.

In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.